FDA Brief

Warning letters Drugs

FDA warning letter to

Fresenius Kabi USA LLC

High riskIssued Sep 22Posted Sep 29Center for Drug Evaluation and Research (CDER)

FDA warns Fresenius Kabi USA over manufacturing failures for sterile injectables at Melrose Park, including endotoxin contamination and media fill failures.

What happened

FDA inspected Fresenius Kabi USA's drug manufacturing facility at 2085 N Hawthorne Ave, Melrose Park, IL from January 27 to February 18, 2026. FDA found inadequate investigations of endotoxin test failures and patient adverse-event reports for famotidine injection, media fill failures, extrinsic contamination such as hair, inadequate visual inspection, and aseptic processing design and practice problems. The firm recalled three famotidine injection batches after retain testing showed an endotoxin failure.

What FDA found

  1. FDA cited the firm for not thoroughly investigating batch failures and discrepancies, including endotoxin (a fever-causing bacterial substance) failures and adverse-event complaints for famotidine injection, and for relying on passing finished-product tests.

    21 CFR 211.192
  2. FDA cited the firm for not following written procedures to prevent microbial contamination of sterile drugs, with media fills that did not adequately simulate maximum interventions and poor aseptic practices.

    21 CFR 211.113(b)
  3. FDA cited the firm for inadequate control procedures to monitor manufacturing output and validate processes, and for aseptic processing areas not adequately sized or separated to prevent contamination or mix-ups.

    21 CFR 211.110(a) and 21 CFR 211.42(c)(10)
  4. FDA cited the firm's visual inspection program as inadequate because it did not classify hair and other non-glass particulates as critical, had low detection probability, and lacked defect limits for specific non-glass particulates.

    21 CFR 211.110(a) and 21 CFR 211.42(c)(10)
  5. FDA cited the firm for aseptic processing lines with limited barrier protection that required frequent high-risk interventions and did not provide adequate separation and protection of the ISO 5 (critical sterile) area.

    21 CFR 211.110(a) and 21 CFR 211.42(c)(10)
  6. FDA cited the firm for not timely investigating at least nine documented incidents since May 2022 of extrinsic biological contamination such as hair and for releasing affected batches to customers.

    21 CFR 211.192

What FDA wants

FDA tells the company to promptly address the violations and provide comprehensive independent assessments and remediation plans covering investigations, CAPA, endotoxin control, environmental monitoring, media fills, visual inspection, aseptic practices, facility/equipment design, supplier quality, and transfer/supply continuity. The provided letter does not state a specific working-day deadline.

Who should pay attention

  • hospitals and clinicians using Fresenius Kabi sterile injectables
  • makers of sterile injectables with similar aseptic lines
  • suppliers of stoppers and packaging components

This is a summary. Read the original letter on fda.gov.

Fresenius Kabi USA LLC's FDA history

Recalls in the last 12 months

Sep 2 Class I Fresenius Kabi USA, LLC
Drug
Tyenne (tocilizumab-aazg) Injection, 400 mg/20 mL (20 mg/mL), 20 mL vial, Rx Only, Manufactured by Fresenius Kabi USA, LLC, Lake Zurich, Illinois, 60047, NDC 65219-594-20.
Presence of particulate matter:An internal investigation at the firm found the product to contain glass particles.
Aug 26 Class I Fresenius Kabi USA, LLC
Drug
Morphine Sulfate Injection, USP, 2 mg /mL, 1 mL single-dose Simplist prefilled syringes, For Intramuscular or Intravenous use, Rx only, Fresenius Kabi, Lake Zurich, IL. Unit of Use NDC Number 76045-004-01; Unit of Sale N…
Labeling: Label Mixup: MicroVault labeled as Morphine 2 mg/1 mL, contains a Prefilled Syringe of Dilaudid 0.5 mg/0.5 mL.
Jul 29 Class II Fresenius Kabi USA, LLC
Drug
Naropin (ropivacaine hydrochloride Injection, USP), 0.5%, 100 mg per 20 mL (5 mg per mL), Twenty-five, 20 mL Single-Dose Vials, Rx only, Fresenius Kabi, Lake Zurich, IL 60047 NDC Tray: 63323-286-23; NDC Vial: 63323-286-…
Presence of Particulate Matter: Hair was found in products
Jul 29 Class II Fresenius Kabi USA, LLC
Drug
Xylocaine (lidocaine HCl Injection, USP), 1%, 200 mg per 20 mL (10 mg per mL), 25 Multiple-Dose Vials, 20 mL, Rx only, Sterile, Fresenius Kabi, Lake Zurich, IL 60047 NDC Tray: 63323-485-27; NDC Vial: 63323-485-01
Presence of Particulate Matter: Hair was found in products
Jul 29 Class II Fresenius Kabi USA, LLC
Drug
Lidocaine HCl Injection, USP, 2%, 100 mg per 5 mL (20 mg per mL), 25 Single Dose Vials, 5 mL per vial, Rx only, Sterile, Fresenius Kabi, Lake Zurich, IL 60047 NDC Tray: 63323-208-05; NDC Vial: 63323-208-01
Presence of Particulate Matter: Hair was found in products
Jul 29 Class II Fresenius Kabi USA, LLC
Drug
Xylocaine (lidocaine HCl Injection, USP), 1%, 500 mg per 50 mL (10 mg per mL), 25 Multiple-Dose Vials, 50 mL, Rx only, Sterile, Fresenius Kabi, Lake Zurich, IL 60047 NDC Tray: 63323-485-57; NDC Vial: 63323-485-03
Presence of Particulate Matter: Hair was found in products
Jul 29 Class II Fresenius Kabi USA, LLC
Drug
Glycopyrrolate Injection, USP, 1 mg per 5 mL (0.2 mg per mL), 25 x 5 mL fill in a 6.5 mL vial, Rx only, Multiple Dose Vials, Fresenius Kabi, Lake Zurich, IL 60047 NDC Tray: 63323-578-05; NDC Vial: 63323-578-07
Presence of Particulate Matter: Hair was found in product
Jun 17 Class III Fresenius Kabi USA, LLC
Drug
Epinephrine Injection, USP, 1mg/mL, 1 mL single-dose vial, Rx only, Fresenius Kabi, Lake Zurich, IL 60047, NDC 63323-696-02 (vial), NDC 63323-696-25 (carton)
Failed Impurities/Degradations Specifications
Jun 10 Class II Fresenius Kabi USA, LLC
Device
The Large Volume Pump (LVP) of the Ivenix Infusion System (IIS). Model Number: LVP-0004.
Potential for the Cassette Loading Lever to break.
Jun 10 Class I Fresenius Kabi USA, LLC
Device
LVP software of the Ivenix Infusion System (IIS); Product Code LVP-SW-0005.
Potential software anomaly that can cause the pump to report a false battery-health value (typically 69%) and trigger a battery-depletion alarm that will shut down the pump unless it is reconnected to AC mains power.
Jun 10 Class I Fresenius Kabi USA, LLC
Device
Ivenix Infusion System (IIS), Large Volume Pump, Model Number: LVP-0004
Fresenius Kabi has been made aware via customer complaints that dropping or severe jarring of the Ivenix LVP may cause damage to internal components that may not be apparent or readily visible and the devices therefore remained in service. More specifically, drops or jarring on a hard surface can cause the touchscreen input cable to loosen, resulting in unintended touchscreen behavior on the LVP, including random screen touches and/or lack of screen responsiveness to user input. Under the reported failure condition, unintended touch inputs may register at arbitrary screen locations without user interaction. These inputs occur intermittently and without a predictable pattern.
Apr 15 Class II Fresenius Kabi USA, LLC
Drug
0.9% Sodium Chloride Injection, USP, (2,250 mg per 250 mL) (9 mg per mL) 250 mL in a 250 mL freeflex bag, Rx only, Fresenius Kabi USA, LLC ("Fresenius Kabi"), Lake Zurich, IL 60047, Unit of Use NDC: 65219-470-05, Unit of…
Lack of Assurance of Sterility
Apr 15 Class II Fresenius Kabi USA, LLC
Drug
0.45% Sodium Chloride Injection, USP, 1.125 grams per 250 mL (4.5 mg per mL), 250 mL in a 250 mL freeflex bag, Rx only, Fresenius Kabi USA, LLC ("Fresenius Kabi"), Lake Zurich, IL 60047, Unit of Use NDC: 63323-626-03, Un…
Lack of Assurance of Sterility
Apr 15 Class II Fresenius Kabi USA, LLC
Drug
0.9% Sodium Chloride Injection, USP 900 mg per 100 mL (9 mg per mL) 500 mL in a Single Dose freeflex bag, 500 mL x 20, Manufactured for: Fresenius Kabi USA, LLC ("Fresenius Kabi"), IL 60047, Unit of Use NDC: 65219-432-20…
Lack of Assurance of Sterility
Apr 15 Class II Fresenius Kabi USA, LLC
Drug
0.9% Sodium Chloride Injection, USP, 0.9% (900 mg per 100 mL) (9 mg per mL) 100 mL in a 100 mL freeflex bag, Rx only, Fresenius Kabi USA, LLC ("Fresenius Kabi"), Lake Zurich, IL 600047, Unit of Use NDC: 65219-468-05, Uni…
Lack of Assurance of Sterility
Apr 15 Class II Fresenius Kabi USA, LLC
Drug
0.9% Sodium Chloride Injection, USP, (4,500 mg per 500 mL) (9 mg per mL) 500 mL in a 500 mL freeflex bag, Rx only, Fresenius Kabi USA, LLC ("Fresenius Kabi"), Lake Zurich, IL 60047, Unit of Use NDC: 65219-472-05, Unit of…
Lack of Assurance of Sterility
Apr 15 Class II Fresenius Kabi USA, LLC
Drug
0.9% Sodium Chloride Injection, USP, 900 mg per 100 mL (9 mg per mL) 100 mL in a Single Dose freeflex bag, Rx only, BD Beckton, Dickson and Company, 1 Beckton Drive, Franklin Lakes, NJ 07417 USA, Distributed by BD, Manuf…
Lack of Assurance of Sterility
Apr 15 Class II Fresenius Kabi USA, LLC
Drug
5% Dextrose Injection, USP 2.5 g per 50 mL (50 mg per mL) 50 mL in a 100 mL freeflex bag, Fresenius Kabi USA, LLC ("Fresenius Kabi"), Unit of Use NDC: 65219-456-05, Unit of Sale NDC Number: 65219-456-60.
Lack of Assurance of Sterility
Apr 15 Class II Fresenius Kabi USA, LLC
Drug
5% Dextrose Injection, USP 12.5 g per 250 mL (50 mg per mL) 250 mL in a 250 mL freeflex bag, Fresenius Kabi USA, LLC ("Fresenius Kabi"), Unit of Use NDC: 65219-458-05, Unit of Sale NDC Number: 65219-458-30.
Lack of Assurance of Sterility
Apr 15 Class II Fresenius Kabi USA, LLC
Drug
5% Dextrose Injection, USP 5 g per 100 mL (50 mg per mL) 100 mL in a 100 mL freeflex bag, Fresenius Kabi USA, LLC ("Fresenius Kabi"), Unit of Use NDC: 65219-464-05, Unit of Sale NDC Number: 65219-464-50.
Lack of Assurance of Sterility

Full company page

Similar letters to other companies

  1. USV Private Limited

    FDA warned USV Private Limited that its sterile injectable manufacturing in Daman, India, had aseptic-processing, facility-design and visible-particulate violations.

    High risk
  2. Baxter International Inc.

    Baxter's Round Lake injectable drug plant violated CGMP (manufacturing quality rules), with cephalosporin cross-contamination and sterile processing failures.

    High risk
  3. Jabil Inc.

    FDA warned Jabil Inc. after an inspection found inadequate investigations of mold and sterility failures at its sterile injectable contract manufacturer.

    High risk
  4. Eugia Pharma Specialities Limited

    FDA warned Eugia Pharma Specialities that flawed aseptic line design and poor aseptic practices at its Kolthur Village plant risk contaminating sterile injectables.

    High risk